This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL's strong product portfolio raises optimism about the stock.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Here's Why Inspire Medical Systems (INSP) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Zacks Industry Outlook Highlights Medical Systems, Clover Health Investments and CareCloud
by Zacks Equity Research
Medical Systems, Clover Health Investments and CareCloud are part of the Zacks Industry Outlook article.
Buy These 3 Medical Info Systems Stocks to Capitalize on GenAI Boom
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Clover Health Investments and CareCloud are expected to gain from the GenAI wave.
Why Inspire Medical Systems (INSP) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Inspire (INSP) Might be Well Poised for a Surge
by Zacks Equity Research
Inspire (INSP) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Inspire Medical (INSP) Q2 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Inspire Medical (INSP) reports strong second-quarter results, reflecting a 30% revenue increase. Its new technology and expanded U.S. presence promise growth and enhanced patient care.
Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Inspire (INSP) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Inspire Medical Systems (INSP) Tops Q2 Earnings Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 328.57% and 0.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical (INSP) Gets FDA Nod for Inspire V System
by Zacks Equity Research
Inspire Medical (INSP) secures FDA approval for its advanced Inspire V therapy system, featuring an innovative neurostimulator and Bluetooth technology for enhanced patient and physician control.
Wall Street's Insights Into Key Metrics Ahead of Inspire (INSP) Q2 Earnings
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Inspire (INSP), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval
by Zacks Equity Research
Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028
by Zacks Equity Research
The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Three Reasons to Retain Inspire Medical (INSP) Stock for Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down
by Zacks Equity Research
Phibro's (PAHC) impressive fiscal 2024 third-quarter performance continues to be driven by the Animal Health segment.
National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.
Inspire (INSP) Loses -31.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Inspire (INSP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.
Inspire (INSP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Inspire (INSP) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.